Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study

Area of Science:

• * Pharmaceutical Sciences
• * Nanotechnology
• * Neuropharmacology

Background:

• * Acyclovir (ACV) is a primary antiviral medication for herpes encephalitis.
• * Effective brain targeting of ACV remains a challenge for optimal therapeutic outcomes.
• * Novel drug delivery systems are needed to improve ACV's efficacy and reduce side effects.

Purpose of the Study:

• * To develop and characterize chitosan-tween 80 coated solid lipid nanoparticles (SLNs) for enhanced brain delivery of acyclovir (ACV).
• * To evaluate the in vitro and in vivo pharmacokinetic performance of ACV-loaded SLNs in a rabbit model.
• * To assess the potential of this nanocarrier system for improved brain targeting of ACV.

Main Methods:

• * Preparation of ACV-loaded SLNs using a microemulsion method with chitosan and tween 80 coating.
• * In vitro characterization of the prepared ACV-SLNs.
• * In vivo pharmacokinetic studies in rabbits comparing coated ACV-SLNs with free ACV solution via intravenous administration.
• * Plasma and brain pharmacokinetic parameter analysis using compartmental and non-compartmental methods.

Main Results:

• * Coated ACV-SLNs demonstrated sustained drug release characteristics.
• * In vivo studies showed a twofold increase in AUC0-∞ and MRT for coated ACV-SLNs compared to free ACV in plasma.
• * The brain to plasma AUC ratio was significantly higher for coated ACV-SLNs (0.22) than for free ACV (0.12), indicating enhanced brain targeting.

Conclusions:

• * Chitosan-tween 80 coated SLNs represent an effective nanocarrier system for improving the brain targeting of acyclovir.
• * This formulation has the potential to enhance the therapeutic efficacy of ACV in treating central nervous system viral infections like herpes encephalitis.
• * Further research into this targeted delivery system could lead to improved treatment strategies for brain disorders.